World's Best Scientists 2026 revealed!

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Medicine 93 10824 10168 1029 982 565 34184

John Radford publications per year

The chart shows the history of publications by John Radford between 1963 and 2025, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. John Radford published across 63 years, from 1963 to 2025, averaging 10.3 papers a year. Output peaked at 43 publications in 2021. 44 of the 651 publications appeared in the last two years.

No. of publications
10 20 30 40
Bar chart. Horizontal axis: year, 1963 to 2025. Vertical axis: number of publications, 0 to 43. Peak 43 publications in 2021. 1963: 1 publication 1964: 0 publications 1965: 0 publications 1966: 0 publications 1967: 0 publications 1968: 0 publications 1969: 0 publications 1970: 0 publications 1971: 0 publications 1972: 0 publications 1973: 0 publications 1974: 0 publications 1975: 0 publications 1976: 0 publications 1977: 0 publications 1978: 0 publications 1979: 0 publications 1980: 0 publications 1981: 0 publications 1982: 0 publications 1983: 1 publication 1984: 0 publications 1985: 1 publication 1986: 0 publications 1987: 0 publications 1988: 2 publications 1989: 3 publications 1990: 4 publications 1991: 9 publications 1992: 6 publications 1993: 8 publications 1994: 4 publications 1995: 6 publications 1996: 4 publications 1997: 8 publications 1998: 7 publications 1999: 18 publications 2000: 13 publications 2001: 17 publications 2002: 6 publications 2003: 12 publications 2004: 8 publications 2005: 24 publications 2006: 15 publications 2007: 20 publications 2008: 24 publications 2009: 9 publications 2010: 13 publications 2011: 14 publications 2012: 14 publications 2013: 24 publications 2014: 26 publications 2015: 27 publications 2016: 25 publications 2017: 38 publications 2018: 27 publications 2019: 28 publications 2020: 20 publications 2021: 43 publications 2022: 41 publications 2023: 37 publications 2024: 27 publications 2025: 17 publications
1963 2025

651 publications in total across all disciplines

View publications per year as a table
John Radford: publications per year, 1963 to 2025
Year Publications
1963 1
1964 0
1965 0
1966 0
1967 0
1968 0
1969 0
1970 0
1971 0
1972 0
1973 0
1974 0
1975 0
1976 0
1977 0
1978 0
1979 0
1980 0
1981 0
1982 0
1983 1
1984 0
1985 1
1986 0
1987 0
1988 2
1989 3
1990 4
1991 9
1992 6
1993 8
1994 4
1995 6
1996 4
1997 8
1998 7
1999 18
2000 13
2001 17
2002 6
2003 12
2004 8
2005 24
2006 15
2007 20
2008 24
2009 9
2010 13
2011 14
2012 14
2013 24
2014 26
2015 27
2016 25
2017 38
2018 27
2019 28
2020 20
2021 43
2022 41
2023 37
2024 27
2025 17
Total 651
Download as CSV

John Radford publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where John Radford sits on this spectrum.

No. of scientists
200 400 600 800
Bar chart with 86 bars. Horizontal axis: publications, 101–120 to 1,796+. Vertical axis: number of scientists, 0 to 922. Most scientists, 922, have 341–360 publications. The last bar groups every scientist with 1,796 publications or more. The highlighted bar, 561–580 publications, is where this scientist sits. 101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101–120 publications 1,796+

This scientist: 565 publications — 68th percentile

68% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

View publications distribution as a table
Number of Medicine scientists by publication count, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
Publications Scientists This scientist
101–120 5
121–140 26
141–160 73
161–180 155
181–200 230
201–220 363
221–240 487
241–260 545
261–280 722
281–300 768
301–320 834
321–340 895
341–360 922
361–380 838
381–400 861
401–420 918
421–440 806
441–460 771
461–480 751
481–500 713
501–520 617
521–540 610
541–560 537
561–580 504 565
581–600 509
601–620 396
621–640 386
641–660 371
661–680 340
681–700 336
701–720 307
721–740 259
741–760 230
761–780 228
781–800 217
801–820 204
821–840 186
841–860 177
861–880 155
881–900 139
901–920 145
921–940 116
941–960 133
961–980 91
981–1,000 96
1,001–1,020 77
1,021–1,040 70
1,041–1,060 63
1,061–1,080 77
1,081–1,100 49
1,101–1,120 54
1,121–1,140 49
1,141–1,160 51
1,161–1,180 35
1,181–1,200 39
1,201–1,220 26
1,221–1,240 37
1,241–1,260 36
1,261–1,280 27
1,281–1,300 32
1,301–1,320 28
1,321–1,340 17
1,341–1,360 30
1,361–1,380 28
1,381–1,400 17
1,401–1,420 21
1,421–1,440 15
1,441–1,460 12
1,461–1,480 12
1,481–1,500 18
1,501–1,520 14
1,521–1,540 17
1,541–1,560 15
1,561–1,580 6
1,581–1,600 2
1,601–1,620 12
1,621–1,640 11
1,641–1,660 8
1,661–1,680 5
1,681–1,700 5
1,701–1,720 10
1,721–1,740 12
1,741–1,760 14
1,761–1,780 6
1,781–1,795 5
1,796+ 100
Download as CSV

John Radford D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where John Radford sits on this spectrum.

No. of scientists
250 500 750 1,000
Bar chart with 75 bars. Horizontal axis: D-Index, 70–71 to 217+. Vertical axis: number of scientists, 0 to 1,027. Most scientists, 1,027, have 82–83 D-Index. The last bar groups every scientist with 217 D-Index or more. The highlighted bar, 92–93 D-Index, is where this scientist sits. 70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70–71 D-Index 217+

This scientist: 93 D-Index — 47th percentile

47% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

View D-Index distribution as a table
Number of Medicine scientists by D-index, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
D-Index Scientists This scientist
70–71 226
72–73 391
74–75 574
76–77 730
78–79 891
80–81 972
82–83 1,027
84–85 1,003
86–87 960
88–89 970
90–91 922
92–93 839 93
94–95 808
96–97 779
98–99 668
100–101 611
102–103 630
104–105 513
106–107 541
108–109 445
110–111 429
112–113 399
114–115 393
116–117 318
118–119 302
120–121 287
122–123 255
124–125 256
126–127 252
128–129 230
130–131 179
132–133 168
134–135 163
136–137 159
138–139 134
140–141 134
142–143 118
144–145 109
146–147 106
148–149 74
150–151 79
152–153 80
154–155 87
156–157 57
158–159 74
160–161 69
162–163 60
164–165 53
166–167 39
168–169 42
170–171 32
172–173 39
174–175 40
176–177 28
178–179 19
180–181 23
182–183 31
184–185 18
186–187 20
188–189 22
190–191 13
192–193 21
194–195 12
196–197 12
198–199 14
200–201 15
202–203 13
204–205 10
206–207 8
208–209 4
210–211 12
212–213 11
214–215 10
216 4
217+ 98
Download as CSV

Overview

John Radford is affiliated with the University of Manchester in the United Kingdom. Their research primarily spans the field of Medicine, with a focus on several critical subfields including Pathology and Forensic Medicine, Oncology, Pulmonary and Respiratory Medicine, Genetics, and Radiology, Nuclear Medicine and Imaging.

Their work extensively covers topics related to Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, Lung Cancer Treatments and Mutations, CAR-T cell therapy research, CNS Lymphoma Diagnosis and Treatment, Viral-associated cancers and disorders, and Monoclonal and Polyclonal Antibodies Research.

Frequent co-authors contributing regularly to their research include:

  • Pier Luigi Zinzani
  • Kirit M. Ardeshna
  • Mehdi Hamadani
  • Brian T. Hess
  • Ranjana H. Advani

Their publications appear predominantly in the following venues:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • Hematological Oncology
  • HemaSphere
  • Journal of Clinical Oncology

Some recent notable papers authored or co-authored by Radford include:

  • Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial, 2020, The Lancet Oncology
  • Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial, 2021, The Lancet Oncology
  • Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma, 2022, New England Journal of Medicine
  • Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma, 2020, Blood
  • Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial, 2021, The Lancet Haematology

Best Publications

  • Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

    Michael L. Wang;Simon Rule;Peter Martin;Andre Goy

  • Rituximab (Anti-CD20 Monoclonal Antibody) for the Treatment of Patients With Relapsing or Refractory Aggressive Lymphoma: A Multicenter Phase II Study

    B. Coiffier;C. Haioun;N. Ketterer;A. Engert

  • Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.

    Robert Chen;Pier Luigi Zinzani;Michelle A. Fanale;Philippe Armand

  • Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma

    Peter Johnson;Massimo Federico;Amy A Kirkwood;Alexander Fossa

  • Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.

    John Radford;Tim Illidge;Nicholas Counsell;Barry Hancock

  • Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

    Joseph M. Connors;Wojciech Jurczak;David J. Straus;Stephen M. Ansell

  • European Phase II Study of Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) for Patients With Newly Diagnosed Mantle-Cell Lymphoma and Previously Treated Mantle-Cell Lymphoma, Immunocytoma, and Small B-Cell Lymphocytic Lymphoma

    James M. Foran;Ama Z. S. Rohatiner;David Cunningham;Razvan A. Popescu

  • Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

    David Cunningham;Eliza A Hawkes;Andrew Jack;Wendi Qian

  • Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.

    J Verweij;A van Oosterom;J.-Y Blay;I Judson

  • Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial

    Ruth Pettengell;Howard Gurney;John A Radford;David P Deakin

  • Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma

    Franck Morschhauser;John Radford;Achiel Van Hoof;Umberto Vitolo

  • Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial

    A. Le Cesne;J.Y. Blay;I. Judson;A. Van Oosterom

  • Myocardial Infarction Mortality Risk After Treatment for Hodgkin Disease: A Collaborative British Cohort Study

    Anthony J. Swerdlow;Craig D. Higgins;Paul Smith;David Cunningham

  • Orthotopic reimplantation of cryopreserved ovarian cortical strips after high-dose chemotherapy for Hodgkin's lymphoma

    John A Radford;B A Lieberman;Daniel R Brison;A R Smith

  • Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma : a study by the EORTC Soft Tissue and Bone Sarcoma Group

    Ian R Judson;John A Radford;Maggie A Harris;Jean-Yves Blay

  • Multicenter phase II study of iodine-131 tositumomab for chemotherapy- relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas

    Julie Marie Vose;Richard L. Wahl;Mansoor Saleh;Ama Z. Rohatiner

  • How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines

    H. G. Laverty;C. Benson;E. J. Cartwright;M. J. Cross

  • Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.

    Michael L. Wang;Kristie A. Blum;Peter Martin;Andre Goy

  • Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.

    Franck Morschhauser;Hervé Tilly;Aristeidis Chaidos;Pamela McKay

  • Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma

    Sally F. Barrington;Wendi Qian;Edward J. Somer;Antonella Franceschetto

Frequent Co-Authors

Peter Johnson
Peter Johnson University of Southampton
David Cunningham
David Cunningham Royal Marsden NHS Foundation Trust
Pier Luigi Zinzani
Pier Luigi Zinzani University of Bologna
Gilles Salles
Gilles Salles Memorial Sloan Kettering Cancer Center
David C. Linch
David C. Linch University College London
Craig H. Moskowitz
Craig H. Moskowitz University of Miami
Nick Thatcher
Nick Thatcher University of Manchester
Peter Hoskin
Peter Hoskin University of Manchester
Massimo Federico
Massimo Federico University of Modena and Reggio Emilia
Caroline Dive
Caroline Dive University of Manchester

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a medical career in the USA opens up a wide range of academic and professional options, especially for those seeking flexible and affordable education. Many students choose online pathways to accelerate or streamline their healthcare careers.

For working nurses aiming to advance, the cheapest dnp programs online allow for doctoral study without the high financial burden of traditional programs. Similarly, those holding a registered nurse license may want to consider what is the cheapest rn to bsn program online to quickly complete their bachelor’s degree at an affordable cost.

If you're coming from a non-nursing background but aspire to advanced practice roles, direct entry np programs for non nurses online offer a fast track into nurse practitioner careers. For those just beginning, researching the easiest rn program to get into can increase your chances of admission and save valuable time.

With the increasing availability of online programs, pursuing a health-related degree is more accessible than ever and can help launch or advance your medical career in the USA.

Best Scientists Citing John Radford

Trending Scientists

Recently Published Articles